Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)

被引:46
作者
Vollmer, J
Jepsen, JS
Uhlmann, E
Schetter, C
Jurk, M
Wader, T
Wüllner, M
Krieg, AM
机构
[1] Coley Pharmaceut Grp, D-40764 Langenfeld, Germany
[2] Danish Canc Soc, Inst canc Biol, Copenhagen, Denmark
[3] Coley Pharmaceut Grp, Wellesley, MA 02481 USA
关键词
D O I
10.1089/154545704322988021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Locked nucleic acid (LNA) is an RNA derivative that when introduced into oligodeoxynucleotides (ODN), mediates high efficacy and stability. CpG ODNs; are potent immune stimulators and are recognized by toll-like receptor-9 (TLR9). Some phosphorothioate antisense ODNs bearing CpG dinucleotides have been shown to possess immune modulatory capacities. We investigated the effects of LNA substitutions on immune stimulation mediated by antisense ODN G3139 or CpG ODN 2006. LNA ODNs were tested for their ability to stimulate cytokine secretion from human immune cells or TLR9-dependent signaling. Phosphorothioate chimeric LNA/DNA antisense ODNs with phosphodiester-linked LNA nucleobases at both ends showed a marked decrease of immune modulation with an increasing number of 3' and 5' LNA bases. In addition, guanosine-LNA and cytosine-LNA or simply cytosine-LNA substitutions in the CpG dinucleotides of ODN 2006 led to strong decrease or near complete loss of immune modulation. TLR9-mediated signaling was similarly affected. These data indicate that increasing amounts of LNA residues in the flanks or substitutions of CpG nucleobases with LNA reduce or eliminate the immune stimulatory effects of CpG-containing phosphorothioate ODN.
引用
收藏
页码:23 / 31
页数:9
相关论文
共 43 条
  • [1] Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
  • [2] 2-U
  • [3] Ballas ZK, 1996, J IMMUNOL, V157, P1840
  • [4] Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
    Bauer, S
    Kirschning, CJ
    Häcker, H
    Redecke, V
    Hausmann, S
    Akira, S
    Wagner, H
    Lipford, GB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) : 9237 - 9242
  • [5] Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design
    Braasch, DA
    Liu, YH
    Corey, DR
    [J]. NUCLEIC ACIDS RESEARCH, 2002, 30 (23) : 5160 - 5167
  • [6] IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1
    BRANDA, RF
    MOORE, AL
    MATHEWS, L
    MCCORMACK, JJ
    ZON, G
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) : 2037 - 2043
  • [7] Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides
    Dias, N
    Stein, CA
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (03) : 263 - 269
  • [8] In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides
    Fluiter, K
    ten Asbroek, ALMA
    de Wissel, MB
    Jakobs, ME
    Wissenbach, M
    Olsson, H
    Olsen, O
    Oerum, H
    Baas, F
    [J]. NUCLEIC ACIDS RESEARCH, 2003, 31 (03) : 953 - 962
  • [9] Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA
    Grünweller, A
    Wyszko, E
    Bieber, B
    Jahnel, R
    Erdmann, VA
    Kurreck, J
    [J]. NUCLEIC ACIDS RESEARCH, 2003, 31 (12) : 3185 - 3193
  • [10] Mechanism and function of a newly identified CpG DNA moth in human primary B cells
    Hartmann, G
    Krieg, AM
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (02) : 944 - 952